Fulcrum Therapeutics Files 8-K on Shareholder Vote
Ticker: FULC · Form: 8-K · Filed: Jun 27, 2025 · CIK: 1680581
| Field | Detail |
|---|---|
| Company | Fulcrum Therapeutics, INC. (FULC) |
| Form Type | 8-K |
| Filed Date | Jun 27, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-vote
Related Tickers: FULC
TL;DR
FULC filed an 8-K about a shareholder vote. Details TBD.
AI Summary
Fulcrum Therapeutics, Inc. filed an 8-K on June 27, 2025, reporting on matters submitted to a vote of security holders as of June 26, 2025. The filing does not contain specific details about the nature of the vote or any outcomes.
Why It Matters
This filing indicates a formal process involving shareholder decisions, which could impact corporate governance or strategic direction.
Risk Assessment
Risk Level: low — The filing is procedural and does not disclose material financial or operational changes.
Key Players & Entities
- Fulcrum Therapeutics, Inc. (company) — Registrant
- June 26, 2025 (date) — Date of earliest event reported
- June 27, 2025 (date) — Date of report
- 26 Landsdowne Street, Cambridge, Massachusetts (address) — Principal executive offices
FAQ
What specific matters were submitted to a vote of Fulcrum Therapeutics' security holders?
The filing does not specify the exact matters that were submitted to a vote of security holders.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on June 26, 2025.
What is the principal executive office address for Fulcrum Therapeutics?
The principal executive office is located at 26 Landsdowne Street, Cambridge, Massachusetts.
What is the Commission File Number for Fulcrum Therapeutics?
The Commission File Number is 001-38978.
What is the IRS Employer Identification Number for Fulcrum Therapeutics?
The IRS Employer Identification Number is 47-4839948.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 27, 2025 regarding Fulcrum Therapeutics, Inc. (FULC).